The hallucinogen derived from Salvia divinorum, salvinorin A, has κ-opioid agonist discriminative stimulus effects in rats

Neuropharmacology

Volumn 53, Issue 4, 2007, Pages 481-486

  Willmore Fordham, Catherine B ^a   Krall, Daniel M ^a   McCurdy, Christopher R ^b   Kinder, David H ^a  

^a OHIO NORTHERN UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Drug discrimination; Kappa opioid; Operant conditioning; Salvia divinorum; Salvinorin A

Indexed keywords

KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NORBINALTORPHIMINE; NORBINALTORPHIMINE DIHYDROCHLORIDE; PSYCHEDELIC AGENT; SALVINORIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG DISCRIMINATION; DRUG EFFECT; DRUG SUBSTITUTION; DYSPHORIA; INSTRUMENTAL CONDITIONING; MALE; MONOTHERAPY; NONHUMAN; PERCEPTION; PRIORITY JOURNAL; RAT; RHESUS MONKEY; SALVIA; SEDATION;

ANIMALS; BENZENEACETAMIDES; DISCRIMINATION LEARNING; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; MALE; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; SALVIA;

EID: 34548010555     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.06.008     Document Type: Article

References (34)

1. Ansonoff M.A., Zhang J., Czyzyk T., Rothman R.B., Stewart J., Xu H., Zjwiony J., Siebert D.J., Yang F., Roth B.L., and Pintar J.E. Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice. Journal of Pharmacology and Experimental Therapeutics 318 (2006) 641-648
2. Barry U., and Zuo Z. Opioids: old drugs for potential new applications. Current Pharmaceutical Design 11 (2005) 1343-1350
3. Braida D., Limonta V., Pegorini S., Zani A., Guerini-Rocco C., Gori E., and Sala M. Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB(1)-cannabinoid receptor involvement. Psychopharmacology (Berlin) 190 (2007) 441-448
4. Bucheler R., Gleiter C.H., Schwoerer P., and Gaertner I. Use of non prohibited hallucinogenic plants: increasing relevance for public health?. Pharmacopsychiatry 38 (2005) 1-5
5. Butelman E.R., Harris T.J., and Kreek M.J. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berlin) 172 (2004) 220-224
6. Butelman E.R., Mandau M., Tidgewell K., Prisinzano T.E., Yuferov V., and Kreek M.J. Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. Journal of Pharmacology and Experimental Therapeutics 320 (2007) 300-306
7. Carlezon W.A., Beguin C., DiNieri J.A., Baumann M.H., Richards M.R., Todtenkopf M.S., Rothman R.B., Ma Z., Lee D.Y., and Cohen B.M.J. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. Journal of Pharmacology and Experimental Therapeutics 316 (2006) 440-447
8. Chavkin C., Sud S., Jin W., Stewart J., Zjawiony J.K., Siebert D.J., Toth B.A., Hufeisen S.J., and Roth B.L. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. Journal of Pharmacology and Experimental Therapeutics 308 (2004) 1197-1203
9. Colpaert F.C. Discriminative stimulus properties of narcotic analgesic drugs. Pharmacology. Biochemistry and Behavior 9 (1978) 863-887
10. Colpaert F.C., Niemegeers C.J., Lal H., and Janssen P.A. Investigations on drug produced and subjectively experienced discriminative stimuli. Life Sciences 16 (1975) 717-727
11. Fantegrossi W.E., Kugle K.M., Valdes L., Koreeda M., and Woods J.H. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behavioral Pharmacology 16 (2005) 627-633
12. Giroud C., Felber F., Augsburger M., Horisberger B., Rivier L., and Mangin P. Salvia divinorum: an hallucinogenic mint which might become a new recreational drug in Switzerland. Forensic Science International 112 (2000) 143-150
13. Glick S.D., Maisonneuve I.M., Raucci J., and Archer S. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Research 681 (1995) 147-152
14. Halpern J.H. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacology and Therapeutics 102 (2004) 131-138
15. Halpern J.H., and Pope H. A vast new source of underground drug information. The American Journal of Psychiatry 158 (2001) 481-483
16. Hanes K.R. Antidepressant effects of the herb Salvia divinorum: a case report. Journal of Clinical Psychopharmacology 21 (2001) 634-635
17. Hunt, D., 1997. Rise of Hallucinogen Use. Research Brief: Publication NCJ 166607; National Institute of Justice, pp. 1-12.
18. Jones R.M., and Portoghese P.S. 5′-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. European Journal of Pharmacology 396 (2000) 49-52
19. Kuzmin A.V., Semenova S., Gerrits M.A., Zvartau E.E., and Van Ree J.M. Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice. European Journal of Pharmacology 321 (1997) 265-271
20. McCurdy C.R., Sufka K.J., Smith G.H., Warnick J.E., and Nieto M.J. Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacology. Biochemistry and Behavior 83 (2006) 109-113
21. Mori T., Nomura M., Yoshizawa K., Nagase H., Narita M., and Suzuki T. Differential properties between TRK-820 and U-50,488H on the discriminative stimulus effects in rats. Life Sciences 75 (2004) 2473-2482
22. Morley J.E., and Levine A.S. Involvement of dynorphin and the kappa opioid receptor in feeding. Peptides 4 (1983) 797-800
23. National Drug Intelligence Center, 2007. Information Bulletin, Microgram XXXVI, 2003.
24. Pfeiffer A., Brantl V., Herz A., and Emrich H.M. Psychotomimesis mediated by kappa opiate receptors. Science 233 (1986) 774-776
25. Przewlocki R., Shearman G.T., and Herz A. Mixed opioid/nonopioid effects of dynorphin and dynorphin related peptides after their intrathecal injection in rats. Neuropeptides 3 (1983) 233-240
26. Roth B.L., Baner K., Westkaemper R., Siebert D., Rice K.C., Steinberg S., Ernsberger P., and Rothman R.B. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences USA 99 (2002) 11934-11939
27. Schenk S., Partridge B., and Shippenberg T.S. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berlin) 144 (1999) 339-346
28. Schuster P., Lieb R., Lamertz C., and Wittchen H.U. Is the use of ecstasy and hallucinogens increasing? Results from a community study. European Addiction Research 4 (1998) 75-82
29. Sheffler D.J., and Roth B.L. Salvinorin A: the ″magic mint″ hallucinogen finds a molecular target in the kappa opioid receptor. Trends in Pharmacologic Sciences 24 (2003) 107-109
30. Valdés L.J. Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. Journal of Psychoactive Drugs 26 3 (1994) 277-283
31. Vortherms T.A., Mosier P.D., Westkaemper R.B., and Roth B.L. Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity. Studies with salvinorin A and the kappa-opioid receptor. Journal of Biological Chemistry 282 (2007) 3146-3156
32. Walsh S.L., Geter-Douglas B., Strain E.C., and Bigelow G.E. Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. Journal of Pharmacology and Experimental Therapeutics 299 (2001) 147-158
33. Wang Y., Tang K., Inan S., Siebert D., Holzgrabe U., Lee D.Y., Huang P., Li J.G., Cowan A., and Liu-Chen L.Y. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. Journal of Pharmacology and Experimental Therapeutics 312 (2005) 220-230
34. Zhang Y., Butelman E.R., Schlussman S.D., Ho A., and Kreek M.J. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berlin) 179 (2005) 551-558